UGT2B10

Across TCGA pan-cancer cohorts, UGT2B10 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of UGT2B10’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where UGT2B10 RNA is repressed in tumor relative to normal tissue. In most cancer types UGT2B10 is over-expressed in tumor, although a few such as LIHC and CHOL show the opposite, repressed pattern.

LIHC, CHOL, and COAD are the cancer types where UGT2B10 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in UGT2B10 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	−2.239	<.001	8	view →
CHOL	Female	All	−8.420	<.001	5	view →
COAD	Female	III,IV	−0.758	<.001	5	view →
LUAD	All	All	+0.036	.001	4	view →
KICH	All	All	−0.046	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

UGT2B10–LIHC

Open the LIHC breakdown →